Diagnostic value of circulating microRNAs for gastric cancer in Asian populations: a meta-analysis
Diagnostic value of circulating microRNAs for gastric cancer in Asian populations: a meta-analysis
复制标题
DOI：
10.1007/s13277-014-2498-4
复制
发表时间：
2014-12-01
期刊：
影响因子：
--
通讯作者：
Liu, Jianchao
中科院分区：
文献类型：
--
作者：
Liu, Lihua;Wang, Shan;Liu, Jianchao
胃癌（GC）是世界范围内死亡率最高的疾病之一，尤其是在东亚。许多研究报道了microRNA（miRNAs）检测对诊断GC的潜在价值，但其结果被证明是不确定的。本荟萃分析旨在评估循环miRNA对GC诊断的诊断价值。在数据库（PubMed、Embase、Web of Science、科克伦图书馆和CNKI）和其他来源中使用与GC、miRNA和诊断相关的关键词组合进行文献检索。使用随机效应模型汇总了单个研究中报告的灵敏度、特异性、阳性似然比（PLR）、阴性似然比（NLR）和诊断比值比（DOR）。采用亚组和荟萃回归分析评估异质性的潜在来源。采用受试者工作特征曲线（SROC）和曲线下面积（AUC）评价miRNA的诊断准确性。这项荟萃分析包括来自20篇出版物的1，279名GC患者和954名健康对照。合并的敏感性、特异性、PLR、NLR、DOR和AUC为0.78（95% CI：0.73-0.81），0.80（95% CI：0.76-0.84）、4.0（95% CI：3.1-6.0）、0.28（95% CI：0.23-0.34）、14（95% CI：10-21）和0.86（95% CI：0.83-0.89）。亚组分析显示，早期（I和II）GC比晚期更容易检测，多个miRNA检测比单个miRNA检测更准确。我们的荟萃分析表明，miRNA对GC具有很高的诊断价值，特别是在其早期阶段（I和II）。此外，多个miRNA检测比单个miRNA检测具有更好的诊断价值。总之，循环中的miRNAs可能被用作非侵入性生物标志物，用于确认亚洲人群中GC检测。
Gastric cancer (GC) accounts for one of the highest mortality worldwide and particularly in East Asia. Many studies have reported on the potential value of microRNAs (miRNAs) detection for diagnosing GC, but their results have proven inconclusive. The present meta-analysis was conducted to assess the diagnostic value of circulating miRNAs for GC diagnosis. A literature search was carried out in databases (PubMed, Embase, Web of Science, The Cochrane Library, and CNKI) and other sources using combinations of keywords relating to GC, miRNAs, and diagnosis. The values of sensitivity, specificity, positive likelihood ratios (PLR), negative likelihood ratios (NLR), and diagnostic odds ratio (DOR) reported in individual studies were pooled using random-effects models. Potential sources of heterogeneity were assessed with subgroup and meta-regression analyses. The summary receiver operating characteristic (SROC) curve and the area under the curve (AUC) were used to assess the diagnosis accuracy of miRNAs. This meta-analysis included 1,279 patients with GC and 954 healthy controls from 20 publications. The pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.78 (95 % CI: 0.73-0.81), 0.80 (95 % CI: 0.76-0.84), 4.0 (95 % CI: 3.1-6.0), 0.28 (95 % CI: 0.23-0.34), 14 (95 % CI: 10-21), and 0.86 (95 % CI: 0.83-0.89), respectively. Subgroup analyses showed that early stages (I and II) GC were more easily detected than later stages and that multiple miRNAs assays were more accurate than single miRNA assays. Our meta-analysis suggests that miRNAs have a high diagnostic value for GC, especially in its early stages (I and II). In addition, multiple miRNAs assays have a better diagnosis value than single miRNA assays. In conclusion, circulating miRNAs might be used as noninvasive biomarkers for the confirmation of GC detection in Asian populations.